0 JBCHEPHARM share price target reports by brokerages below. See what is analyst's view on JBCHEPHARM share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
We expect return ratios and operating margins to improve further, coupled with positive cash-flows and its debt-free status, rendering valuations attractive as the stock currently trades at a discount to its peers. We maintain a Buy, with a higher target of Rs 455 (earlier Rs 416) based on14x FY21e earnings.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.